Morgan Stanley resumes Lakefront at Equal Weight after Ouro buyout
Seeking Alpha ·
Morgan Stanley on Friday resumed its coverage of Lakefront Biotherapeutics ( LKFT ), a biotech formerly known as Galapagos, with an Equal Weight rating and $30 target, citing its Ouro Medicines buyout in June. The $1.7B deal, partly funded by Gilead (
DYAX Investor Sentiment
Bullish (Long) 46% · Bearish (Short) 54%
266 participants
Related News
- Update: Equity Markets Rise Intraday as Traders Track Middle East Developments
- LRE Celebrates $1.5-Billion Investment in 725-MW Oklahoma Solar Fleet
- Sector Update: Financial Stocks Rise Friday Afternoon
- Financials sector is overheated as big names prepare to release earnings reports – analysts
- Can Saving $300 a Month Buy You a Financially Secure Retirement? Here's the Math.
- Google, Amazon Increase Data-Center Capacity Plans